Chime Financial, a leading U.S. neobank, files for Nasdaq IPO, highlighting growth and regulatory risks.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
Topuria and Oliveira to headline UFC 317 in June 2025 for the vacant lightweight title, while Pantoja defends his flyweight belt against Kara-France in the co-main event.
Chime Financial, a leading U.S. neobank, files for Nasdaq IPO, highlighting growth and regulatory risks.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
Topuria and Oliveira to headline UFC 317 in June 2025 for the vacant lightweight title, while Pantoja defends his flyweight belt against Kara-France in the co-main event.